Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study to Assess the Safety and Tolerability of ECI-006 mRNA Immunotherapy by Intranodal Administration in Melanoma: (1) Following Surgical Resection, and (2) in Patients With Stable Disease After Standard of Care Immunotherapy Treatment

NCT03394937 is registered in ClinicalTrials.gov with eTheRNA immunotherapies as lead sponsor.

NCT NCT03394937
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03394937 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study to Assess the Safety and Tolerability of ECI-006 mRNA Immunotherapy by Intranodal Administration in Melanoma: (1) Following Surgical Resection, and (2) in Patients With Stable Disease After Standard of Care Immunotherapy Treatment
Lead sponsor
eTheRNA immunotherapies
Phase
Phase 1
Overall status
Terminated
Start date
June 27, 2017
Completion date
January 29, 2021
Enrollment
21 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma